Last reviewed · How we verify
Placebo to dupilumab
Dupilumab is a monoclonal antibody that blocks the action of interleukin-4 (IL-4) and interleukin-13 (IL-13), which are key cytokines involved in the inflammatory process.
Dupilumab is a monoclonal antibody that blocks the action of interleukin-4 (IL-4) and interleukin-13 (IL-13), which are key cytokines involved in the inflammatory process. Used for Moderate to severe atopic dermatitis, Asthma with an eosinophilic phenotype, Chronic rhinosinusitis with nasal polyps.
At a glance
| Generic name | Placebo to dupilumab |
|---|---|
| Sponsor | AbbVie |
| Drug class | IL-4/IL-13 inhibitor |
| Target | IL-4Rα |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
By blocking IL-4 and IL-13, dupilumab reduces inflammation and prevents the activation of various immune cells, including mast cells and eosinophils. This leads to a decrease in the production of IgE antibodies and a reduction in the symptoms associated with allergic diseases.
Approved indications
- Moderate to severe atopic dermatitis
- Asthma with an eosinophilic phenotype
- Chronic rhinosinusitis with nasal polyps
Common side effects
- Injection site reactions
- Headache
- Nausea
- Fatigue
- Musculoskeletal pain
Key clinical trials
- A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease. (PHASE4)
- Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC) (PHASE3)
- Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma (PHASE4)
- Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS) (PHASE3)
- A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) (PHASE2)
- A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis (PHASE2)
- A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines (PHASE3)
- Dupilumab Effects Against Aeroallergen Challenge (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to dupilumab CI brief — competitive landscape report
- Placebo to dupilumab updates RSS · CI watch RSS
- AbbVie portfolio CI